Robert Lanza, Chief Scientific Officer at Ocata Therapeutics, Inc. (OCAT), sold 25,000 shares at $8.25 ($207K) on 2015-11-10, disclosed to the SEC on 2015-11-10.
Scheduled sale ($207k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.25 | 15,000 | $124K | 59.7% |
| 2 | $8.36 | 10,000 | $84K | 40.3% |
| Total | $8.29 avg | 25,000 | $207K | 100% |
| Filing → |
| ACTC | SELL | 2012-08-01 | $160K | — | Filing → |
| ACTC | SELL | 2012-01-25 | $1.4M | — | Filing → |
| ACTC | SELL | 2011-09-30 | $109K | — | Filing → |